Trial Profile

Xience V at WFUBMC: Real World Outcomes Using Second Generation DES.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Paclitaxel; Sirolimus
Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
Focus Adverse reactions

Most Recent Events

07 Oct 2013 Status changed from recruiting to completed.
23 Oct 2012 Planned End Date changed to 1 Dec 2010 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..
23 Oct 2012 Planned initiation date changed to 1 Jul 2007 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com